Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation

Patent metadata

Field	Value
Publication number	US-RE46912-E
Application number	US-200714537565-A
Country	US
Kind code	E1
Filing date	May 14, 2007
Priority date	Aug 4, 2006
Publication date	Jun 26, 2018
Grant date	Jun 26, 2018

Abstract

The present invention relates to a lactic acid bacterium isolated from human mother's milk, more precisely a Lactobacillus gasseri BNR17 strain that is isolated from Korean mother's milk and has excellent probiotic activity including acid resistance, bile acid resistance and antimicrobial activity and weight gaining inhibitory effect as well. Again, the Lactobacillus gasseri BNR17 of the present invention has excellent acid resistance, bile acid resistance, enteric absorption activity and antimicrobial activity against pathogenic microorganisms, in addition to the weight gaining inhibitory effect by synthesizing indigestible polysaccharides from monosaccharides included in food taken and releasing the synthesized polysaccharides out of the body. Therefore, the strain of the invention, owing to such beneficiary effects, can be effectively used not only for the production of fermented milk, other fermented food products and animal feeds but also for the production of live cell products and food additives for preventing weight gaining.

First claim

What is claimed is:

1. A Lactobacillus gasseri BNR17 strain of a biologically pure culture deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP.

2. The Lactobacillus gasseri BNR17 strain according to claim 1 , wherein the strain contains 16S rRNA sequence represented by SEQ ID NO: 1.

3. A composition containing an effective dose of the Lactobacillus gasseri BNR17 of claim 1 .

4. The composition according to claim 3 , wherein the composition is selected from the group consisting of food, food additive, animal feed and animal feed additive.

5. The composition according to claim 4 , wherein the animal feed additive contains at least one selected from the group consisting of other non-pathogenic microorganisms, enzymes and a mixture thereof.

6. A pharmaceutical composition comprising an effective dose of the Lactobacillus gasseri BNR17 of claim 1 strain in an enteric coating, wherein the L. gasseri BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP.

7. A culture solution of the Lactobacillus gasseri BNR17 of claim 1 .

8. A method for inhibiting weight gain comprising administering to a subject an effective dose amount of the Lactobacillus gasseri BNR17 of claim 1 strain, wherein the L. gasseri BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP.

9. A fermented food product comprising Lactobacillus gasseri BNR17 strain, wherein the L. gasseri BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP.

10. The fermented food product according to claim 9, wherein the fermented food product is a dairy product.

11. A fermented food product having a bacterial component, the bacterial component consisting essentially of Lactobacillus gasseri BNR17 strain, wherein the L. gasseri BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP.

12. The fermented food product according to claim 11, wherein the fermented food product is a dairy product.

13. A dry powder comprising live Lactobacillus gasseri cells and a protectant that inhibits death of the Lactobacillus gasseri cells during a drying step, wherein the live Lactobacillus gasseri cells are of the Lactobacillus gasseri BNR17 strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP, and wherein the protectant comprises 5 weight % powdered skim milk, 2.5 weight % of whey, and 5 weight % of sucrose of the total weight of the dry powder.

14. A food product comprising the dry powder of claim 13.

15. A feed product for a non-human animal comprising an animal feedstock and Lactobacillus gasseri BNR17 strain, wherein the L. gasseri BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP.

16. A tablet or capsule comprising the dry powder of claim 13.

17. The tablet or capsule according to claim 16, wherein the tablet or capsule further comprises a pharmaceutically acceptable carrier or excipient.

18. A formulation comprising Lactobacillus gasseri BNR17 strain, a diluent, a high-fiber additive, an encapsulant, and a lipid, wherein the L. gasseri BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP.

19. A method for treating obesity or inhibiting weight gain in an adult human, the method comprising administering to the human a composition comprising Lactobacillus gasseri BNR17 strain, wherein the L. gasseri BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP.

20. A method for inhibiting saccharide absorption in an adult mammal, the method comprising administering to the mammal a composition comprising Lactobacillus gasseri BNR17 strain, wherein the L. gasseri BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP.

21. A method for inhibiting weight gain or treating obesity in a non-human mammal, comprising administering to the mammal a composition comprising Lactobacillus gasseri BNR17 strain, wherein the L. gasseri BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP.

22. The method according to claim 21, comprising administering 0.1-10 g/day of the Lactobacillus gasseri BNR17.

23. The pharmaceutical composition according to claim 6, wherein the L. gasseri BNR17 strain inhibits weight gain.

24. The dry powder of claim 13, wherein the protectant further comprises 10 weight % trehalose, 10 weight % maltodextrin, and 7.5 weight % lactose.

25. The feed product of claim 15, wherein the feed product further comprises one or more selected from the group consisting of a diluent, a high-fiber additive, an encapsulant, a lipid, an enzyme and a non-pathogenic microorganism.

26. The feed product of claim 25, wherein the enzyme is selected from the group consisting of phytase, cellulose, xylase, maltase, invertase, and a combination thereof.

27. The feed product of claim 25, wherein the non-pathogenic organism is Aspergillus oryzae.

28. A method of producing a food product, comprising mixing a dry powder comprising live Lactobacillus gasseri cells and a protectant that inhibits death of the Lactobacillus gasseri cells during a drying step, with a food, wherein the live Lactobacillus gasseri cells are of the Lactobacillus gasseri BNR17 strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP.

29. The method of claim 28, wherein the protectant comprises 5 weight % powdered skim milk, 2.5 weight % of whey, and 5 weight % of sucrose of the total weight of the dry powder.

Assignees

• Bioneer Corp

Inventors

• Kang Ji Hee
• You Byeung I
• Yun Sung I
• Park Han O

Classifications

• C07K14/335

  from Lactobacillus (G) · CPC title

• A23L33/18

  Peptides; Protein hydrolysates · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A23L33/135

  Bacteria or derivatives thereof, e.g. probiotics · CPC title